Tags

Type your tag names separated by a space and hit enter

The fixed combination of fortified vancomycin and amikacin ophthalmic solution--VA solution: in vitro study of the potency and stability.
Cornea. 2005 Aug; 24(6):717-21.C

Abstract

PURPOSE

We compared the in vitro potency and stability of a fixed combination of vancomycin and amikacin solution (VA solution) with amikacin or vancomycin solution.

METHODS

Solutions of 2% amikacin (20 mg/mL) and of 5% vancomycin (50 mg/mL) and VA solution (each 1 mL contained 20 mg of amikacin and 50 mg of vancomycin) were prepared from parenteral antibiotics by reconstituting them with sterile injection water and refrigerated (4 degrees C) in the dark. Triplicate 5-mL portions of each solution were tested before storage and 7 and 14 days after preparation for potency of antimicrobial activity by the disk diffusion method and for stability.

RESULTS

There were no significant differences in the diameter of zones of inhibition of VA solution compared with amikacin or vancomycin solution within a 2-week period. Visual inspection revealed that all solutions remained clear, colorless, and particle-free at 4 degrees C throughout the study period. For osmolarity, the VA solution was much higher than that of either amikacin or vancomycin solution at all tested times and more near the well-tolerated range of human eyes. There were no significant differences at days 0, 7, or 14 for either vancomycin, amikacin, or VA solution. For pH, the VA solution was higher than that of vancomycin solution (nearly equal to that of amikacin solution) at each time and more near the level of normal tear film. The pH did not differ significantly for either vancomycin, amikacin, or VA solution at all tested times.

CONCLUSIONS

The vancomycin and amikacin ophthalmic solutions can be mixed together with the same potency and stable physical properties. It may be useful in the treatment of bacterial keratitis pending clinical trials to determine its effectiveness and safety.

Links

Publisher Full Text
Aggregator Full Text

Authors+Show Affiliations

Lin JM
Department of Ophthalmology, China Medical University Hospital, Taichung, Taiwan.
Tsai YY
No affiliation info available
Fu YL
No affiliation info available

MeSH

AmikacinAnti-Bacterial AgentsColony Count, MicrobialDrug CombinationsDrug StabilityHydrogen-Ion ConcentrationMicrobial Sensitivity TestsOphthalmic SolutionsOsmolar ConcentrationPseudomonas aeruginosaStaphylococcus epidermidisStreptococcus pneumoniaeVancomycin

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

16015092

Citation

Lin, Jane-Ming, et al. "The Fixed Combination of Fortified Vancomycin and Amikacin Ophthalmic solution--VA Solution: in Vitro Study of the Potency and Stability." Cornea, vol. 24, no. 6, 2005, pp. 717-21.
Lin JM, Tsai YY, Fu YL. The fixed combination of fortified vancomycin and amikacin ophthalmic solution--VA solution: in vitro study of the potency and stability. Cornea. 2005;24(6):717-21.
Lin, J. M., Tsai, Y. Y., & Fu, Y. L. (2005). The fixed combination of fortified vancomycin and amikacin ophthalmic solution--VA solution: in vitro study of the potency and stability. Cornea, 24(6), 717-21.
Lin JM, Tsai YY, Fu YL. The Fixed Combination of Fortified Vancomycin and Amikacin Ophthalmic solution--VA Solution: in Vitro Study of the Potency and Stability. Cornea. 2005;24(6):717-21. PubMed PMID: 16015092.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The fixed combination of fortified vancomycin and amikacin ophthalmic solution--VA solution: in vitro study of the potency and stability. AU - Lin,Jane-Ming, AU - Tsai,Yi-Yu, AU - Fu,Ya-Lin, PY - 2005/7/15/pubmed PY - 2005/9/16/medline PY - 2005/7/15/entrez SP - 717 EP - 21 JF - Cornea JO - Cornea VL - 24 IS - 6 N2 - PURPOSE: We compared the in vitro potency and stability of a fixed combination of vancomycin and amikacin solution (VA solution) with amikacin or vancomycin solution. METHODS: Solutions of 2% amikacin (20 mg/mL) and of 5% vancomycin (50 mg/mL) and VA solution (each 1 mL contained 20 mg of amikacin and 50 mg of vancomycin) were prepared from parenteral antibiotics by reconstituting them with sterile injection water and refrigerated (4 degrees C) in the dark. Triplicate 5-mL portions of each solution were tested before storage and 7 and 14 days after preparation for potency of antimicrobial activity by the disk diffusion method and for stability. RESULTS: There were no significant differences in the diameter of zones of inhibition of VA solution compared with amikacin or vancomycin solution within a 2-week period. Visual inspection revealed that all solutions remained clear, colorless, and particle-free at 4 degrees C throughout the study period. For osmolarity, the VA solution was much higher than that of either amikacin or vancomycin solution at all tested times and more near the well-tolerated range of human eyes. There were no significant differences at days 0, 7, or 14 for either vancomycin, amikacin, or VA solution. For pH, the VA solution was higher than that of vancomycin solution (nearly equal to that of amikacin solution) at each time and more near the level of normal tear film. The pH did not differ significantly for either vancomycin, amikacin, or VA solution at all tested times. CONCLUSIONS: The vancomycin and amikacin ophthalmic solutions can be mixed together with the same potency and stable physical properties. It may be useful in the treatment of bacterial keratitis pending clinical trials to determine its effectiveness and safety. SN - 0277-3740 UR - https://www.unboundmedicine.com/medline/citation/16015092/The_fixed_combination_of_fortified_vancomycin_and_amikacin_ophthalmic_solution__VA_solution:_in_vitro_study_of_the_potency_and_stability_ L2 - http://dx.doi.org/10.1097/01.ico.0000154231.10994.6d DB - PRIME DP - Unbound Medicine ER -